Benefícios não contraceptivos do Sistema Intrauterino Liberador de Levonorgestrel na endometriose

Maria Virgínia de Oliveira e Oliveira, Aline de Paula Souza Bezerra de Lima, Daniela Bruno Conforti, Lucas Kieling Bittencourt, Marcella Rocha Machado de Oliveira, Veridiana Tagliari de Angelo
In: UNILUS Ensino e Pesquisa · 2015 · vol. 12(27) , pp. 42–48 · W2991994679
article OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

The levonorgestrel-releasing intrauterine system effectively reduces endometriosis-related pain, menstrual bleeding, and recurrence, while improving quality of life and bone density.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

The paper set out to identify non-contraceptive benefits of the levonorgestrel-releasing intrauterine system (SIU-LNG) for the treatment of endometriosis, using a search of national and international literature in MEDLINE, PubMed, and LILACS from January to March 2014 with terms including “endometriosis” and “SIU-LNG.” It reports that SIU-LNG provides control of endometriosis-related pain with effects comparable to GnRH analogs, decreasing chronic pelvic pain, dysmenorrhea, and dyspareunia, and also reducing menstrual bleeding and improving quality of life, with lower recurrence after laparoscopic surgery. The discussion further notes additional reported effects including disease control and potential reductions in cardiovascular risk markers and positive effects on bone mineral density. The paper concludes that SIU-LNG appears promising, while randomized trials with larger participant numbers are needed to establish it as a standard treatment, and this paper is centrally about endometriosis — specifically reviewing non-contraceptive benefits of SIU-LNG for endometriosis management.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objetivo: Identificar beneficios nao contraceptivos do Sistema Intrauterino Liberador de Levonorgestrel no tratamento da endometriose. Metodologia: Busca por artigos nacionais e internacionais nas bases MEDLINE, PubMed e LILACS entre janeiro a marco de 2014, utilizando palavras-chave “endometriose”, “SIU-LNG”, “endometriosis” e “LNG-IUS”. Discussao: O SIU-LNG possui efeito similar ao analogo do GnRH no controle da dor causada pela endometriose, diminuindo dor pelvica cronica, dismenorreia e dispareunia. Apresenta efeito na reducao do sangramento menstrual, controle da doenca, aumento da qualidade de vida e diminuicao da recorrencia apos cirurgia laparoscopica. Observa-se reducao do risco cardiovascular e efeito positivo na densidade mineral ossea. Conclusao: O tratamento com SIU-LNG parece ser promissor, entretanto sao necessarios trabalhos randomizados com maior numero de participantes para reconhecimento como tratamento padrao da endometriose.
Full text 5,942 characters · extracted from oa-html · click to expand
Benefícios não contraceptivos do Sistema Intrauterino Liberador de Levonorgestrel na endometriose Resumo Objetivo: Identificar benefícios não contraceptivos do Sistema Intrauterino Liberador de Levonorgestrel no tratamento da endometriose. Metodologia: Busca por artigos nacionais e internacionais nas bases MEDLINE, PubMed e LILACS entre janeiro a março de 2014, utilizando palavras-chave “endometriose”, “SIU-LNG”, “endometriosis” e “LNG-IUS”. Discussão: O SIU-LNG possui efeito similar ao análogo do GnRH no controle da dor causada pela endometriose, diminuindo dor pélvica crônica, dismenorréia e dispareunia. Apresenta efeito na redução do sangramento menstrual, controle da doença, aumento da qualidade de vida e diminuição da recorrência após cirurgia laparoscópica. Observa-se redução do risco cardiovascular e efeito positivo na densidade mineral óssea. Conclusão: O tratamento com SIU-LNG parece ser promissor, entretanto são necessários trabalhos randomizados com maior número de participantes para reconhecimento como tratamento padrão da endometriose. Texto completo: PDFReferências Kim ML, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstetric Gynecoly Science. 2013 Mar;56(2):67-75. Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Preference Adherence. 2013 Ago 9;7:777-85. Figueiredo J, Nascimento R. Avaliação da qualidade de vida de pacientes portadoras de endometriose após inserção do Sistema Intra-Uterino Liberador de Levonorgestrel (SIU-LNg). ACM arq. catarin. med;37(4):20-26, set.-dez. 2008. Williams Schorge J. et al. Ginecologia de Williams 2008 cap 10 pg 225-240 Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010 Jun;50(3):273-9. Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol. 2008 Oct;20(5):464-9. Crosignani PG. Intrauterine devices and intrauterine systems. Human Reproduction Update, Vol.14, No.3 pp. 197-208, 2008. Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009 Jun;5(3):561-74. Epub 2009 Aug 3. Speroff L, Glass RH, Kase NG. Endocrinologia Ginecológica Clinica e Infertilidade. Anpalagan A, Condous G. Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain? J Minim Invasive Gynecol. 2008 Nov-Dec;15(6):663-6. Bayer LL, Hillard PJ. Use of levonorgestrel intrauterine system for medical indications in adolescents. J Adolesc Health. 2013 Apr;52(4 Suppl):S54-8. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. Hum Reprod. 2013 Jul;28(7):1953-60. Yoost J.et al.Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol. 2013 Apr;26(2):120-4. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010 Nov;82(5):396-403. Engemise SL. et al. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):101-6. Lan S. et al. Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis. J Int Med Res. 2013 Jun;41(3):548-58. Deng S. et al. Effects of Progesterone and Progestin on Expression of Regulated on Activation, Normal T Cell Expressed and Secreted in Eutopic Endometrium from Patients with Endometriosis. [S.I.]. 2008. Sheng J. et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009 Mar;79(3):189-93. Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012 Jan;91(1):3-9. Bragheto AM. et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007 Sep;76(3):195-9. Ferreira RA. et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010 Feb;81(2):117-22 Ozdegirmenci O. et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011 Feb;95(2):497-502. Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 2010 Aug 9;1:45-58. Apontamentos - Não há apontamentos. Direitos autorais 2016 Revista UNILUS Ensino e Pesquisa - RUEP ISSN (impresso): 1807-8850 ISSN (eletrônico): 2318-2083 Periodicidade: Trimestral Primeiro trimestre, jan./mar., submissões até 31 de março, publicação da edição até 15 de agosto. Segundo trimestre, abr./jun., submissões até 30 de junho, publicação da edição até 15 de outubro. Terceiro trimestre, jul./set., submissões até 30 de setembro, publicação da edição até 15 de janeiro. Quarto trimestre, out./dez., submissões até 31 de dezembro, publicação da edição até 15 de abril. Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional. Indexadores Estatística de Acesso à RUEP Monitorado desde 01 de dezembro de 2025. Monitorado desde 22 de novembro de 2016.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (18)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK